30 closest matches · ranked by relevance
Pulmonary Arterial Hypertension
Primary: Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio) — 0.8; 0.75; 0.61; 0.73 Rp:Rs ratio — p=0.9
Pulmonary Hypertension, Familial Persistent, of the Newborn
Primary: Time on Inhaled Nitric Oxide (iNO) Treatment After Initiation of Intravenous (IV) Study Drug For Participants Without Treatment Failure — 4.1; 4.1 days — p=0.9850
Congenital Diaphragmatic Hernia · Persistent Pulmonary Hypertension of the Newborn · Hypoxemic Respiratory Failure
Primary: Oxygenation Response — 4.2; 2.6 Change in Oxygenation Index
Pulmonary Arterial Hypertension · Hypertension, Pulmonary
Primary: Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) at Week 16 — 18.567; -4.113 wood units*meter^2
Pulmonary Hypertension, Persistent, of the Newborn
Primary: Number of Participants With Physical Examination Abnormalities at Month 12 — 0 participants
Bronchopulmonary Dysplasia
Primary: Combined Endpoint of Bronchopulmonary Dysplasia (BPD) or Mortality — 1; 2; 24; 25 Participants
Pulmonary Arterial Hypertension, Children
Primary: Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Intent To Treat Population — 6.44; 13.40; 10.58; 10.24 percent change — p=0.056
Portopulmonary Hypertension
Primary: Change in Pulmonary Vascular Resistance — 7.1 percent difference from baseline
Pulmonary Hypertension · Heart Failure, Diastolic
Primary: Change in Pulmonary Vascular Resistance (PVR) — 0.77; 0.40; -0.39 Woods units — p=0.002
Bronchopulmonary Dysplasia of Newborn
Primary: Safety Based Upon Number of Participants With Hypotension — 1; 0; 0; 0 Participants
Pulmonary Hypertension
Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04
Hypoplastic Left Heart Syndrome · Hypoplastic Right-sided Heart Complex
Primary: Area Under the Curve for Ambrisentan Plasma Concentration — 7871.46 ng*hr/mL
Pulmonary Arterial Hypertension
Primary: Difference in Ambulatory 6 Minute Walk Distance (6MWD) Pulmonary Artery (PA) Pressures (Systolic, Diastolic, Mean) Between the Post-intervention (iNO+) and…
Pulmonary Arterial Hypertension
Primary: Change From Baseline to End of Study (EOS) in Height for Age. — -0.8; 0.32; -0.64; -0.74 Z-score
Pulmonary Arterial Hypertension
Primary: Participants >=2 Years of Age: Observed Steady-State Trough (Pre-dose) Plasma Concentration of Macitentan and Aprocitentan (Active Metabolite) at Week 12 Based on Body…
Pulmonary Arterial Hypertension
Primary: 6-minute-walk Distance (6MWD) — 330.0; 328.6 meters — p=0.7883
Bronchopulmonary Dysplasia
Primary: Safety as Determined by Adverse Event Experienced by Participants — 71; 83; 53; 60 Events
Pulmonary Hypertension
Primary: Dose-limiting Toxicities — 0; 0; 0; 0 Participants
Heart Disease
Primary: Maximum Sildenafil Plasma Concentration — 181; 515; 545; 202 ng/mL
Pulmonary Hypertension
Primary: Maximum Change From Baseline in Supine Systolic Blood Pressure (SBP) Within 4 Hours Post-dose at Visit 6 (Week 12) — -20.70; -20.20 mmHg
Pulmonary Arterial Hypertension
Primary: Number of Participants With Side Effects and/or Adverse Events — 0 participants
Portopulmonary Hypertension
Primary: Relative Change From Baseline to Week 12 in Pulmonary Vascular Resistance (PVR). — 0.63; 0.98 ratio — p=0.0001
Pulmonary Arterial Hypertension · Right Heart Failure
Primary: Change in Six-minute Walk Distance — -17.0; 4.7 meters
Sleep Apnea, Obstructive · Hypertension, Pulmonary · Heart Failure
Primary: Pulmonary Artery Systolic Pressure. — 58.6; 62.7; 42.8; 57.5 mmHg
Thalassemia · Hypertension, Pulmonary
Primary: Change in Six-minute Walk Test (6MWT) Distance From Baseline to Week 12 Among Sildenafil Group — -1.38 meters — p=0.97
Hypertension · Pulmonary Arterial Hypertension · Familial Primary Pulmonary Hypertension
Primary: Transthoracic Echocardiogram (ECHO)-Based Change in the Tricuspid Annular Plane Systolic Excursion (TAPSE) Measurement — 2.244; 2.244; 2.300; 2.212 mm
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24, as Measured by Right Heart Catheterization (RHC) — 35; -28; -21; 6 dyne*sec/cm^5 — p== 0.214
Pulmonary Arterial Hypertension
Primary: Pulmonary Vascular Resistance (PVR) — 6.7 woods unit
Pulmonary Artery Hypertension
Primary: Change From Baseline to Week 24 in Pulmonary Vascular Resistance (PVR) — 21.2; -74.9 dyne•s/cm^5 — p=0.0310
Hypertension, Pulmonary
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAE) — 229; 108; 56; 138 Participants